Biodiversity uncovered by Zaman, N & Heinrich, M
Biodiversity uncovered
The world is becoming increasingly aware of the importance
of exploring the biodiversity of rainforests and of preserving
traditional medical knowledge for developing new drugs.
Nuruz Zaman and Michael Heinrich explain
According to the WorldHealth Organization, for75-90% of the rural popu-lations of the world, thelocal herbalist and other
traditional healers are the only source
of medical care.w1 This translates into
three billion people for whom medical
care consists of wild harvested
medicines provided by local traditional
healers.
Even considering these facts as an
eye opener, what’s possibly more
startling is that many of the drugs that
clinical medicine is so familiar with
were in fact discovered from the herbal
remedies of those indigenous people
across the world. Well established
drugs, such as aspirin, codeine, and qui-
nine, were all developed from plants
used medicinally for centuries by
various civilisations.
Of the approximately 265 000
flowering species of plants on the
planet, less than 1% have been studied
in any detail to the point of understand-
ing their composition and medicinal
value.w2 About half of all plant biodiver-
sity exists in primary rainforests, like
the Amazon. But with deforestation
and the rapid cultural and linguistic
changes happening around the world,
we are not only losing the vast
resources of the forests but also the
knowledge of the indigenous people.
This is a catastrophic destruction,
similar to the burning of the great
libraries of Alexandria or Baghdad, in
historic terms.
The pharmaceutical industry must,
therefore, be able to work effectively
with local people to present an alterna-
tive sustainable economic model to
enrich our technological medicine and
also to preserve the historical knowl-
edge and the wealth of the rainforests
in the long term.w3
The interest in ethnopharmaco-
logical research has had a chequered
history. Large drug companies had a
considerable interest in it during the
1990s but moved to other groups of
compounds in the first years of the new
millennium. Recently, a renewed inter-
est in natural products and their
sources has become apparent.w4 As well
as from technological improvements,
modern laboratory techniques, and
enhanced understanding of pharma-
cological targets,w5 the impetus has
come from the continual deforestation.
Recent studies and publications about
ethnopharmacology have stimulated
many lines of interdisciplinary
research.w5 w6
A key factor in the long term
successful relationship between tradi-
tional cultures and global drug compa-
nies involves the protection of intellec-
tual property rights, and, in particular,
the group’s traditional knowledge, to
prevent the threat of exploitation and
to protect the interests of the healers
and their communities. Increasing
demands are apparent among
researchers within indigenous cul-
tures.w8 w9 In the development of the
candidate drug prostratin, the National
Cancer Institute and Brigham Young
University have guaranteed that, in case
of a successful development, a consid-
erable proportion of any royalties
earned by the drug would be returned
to the Somoan people who are the tra-
ditional keepers of this knowledge. To
many cultures, protecting the forests
around them is at least as important as
the future potential of receiving any
money, however.w2
An example of biodiversity driven
drug discovery activities is provided by
the US company Merck Sharp and
Dome, which, for many decades, suc-
cessfully used natural products in its
search for new drug leads (potentially
active biochemicals). The company dis-
continued all its direct natural product
research in 2001, however. As for other
pharmaceutical companies, the struc-
tural diversity of natural products has
been considered an important advan-
tage. On the other hand, research on
natural products is slower (and there-
fore more costly) and there is always the
risk of not being able to get enough
material for resupplying the drug
discovery pipeline with larger amounts
of the original material. In the early
1990s, Merck Sharp and Dome linked
up with Costa Rica’s National Institute
of Biodiversity and started a systematic
search for now drug leads from the
rainforest.w11
The project was established in
1989 in Santo Domingo, Costa Rica.
Importantly, some 4% of the world’s
terrestrial plant species can be found
in this 51 000 km2 territory. Part of this
project involves the government
allocating a quarter of Costa Rican
Territory over two decades to an
integrated system of protected and
privately conserved wild lands. The
project also pioneered the use of para-
taxonomists, local people with suffi-
cient training to differentiate between
species, to combat the shortage of
actual taxonomists. The institute has
successfully invested in local people
and enriched the country’s biodiversity
inventory. A groundbreaking collabora-
tion with Merck lead to an investment
of $1m (£550 000; €820 000) into the
project.w11 Currently, the institute con-
tinues to establish smaller collaborative
agreements with academic and private
institutions in North America and
Europe. With the renewed interest in
such approaches, new drug leads from
the rainforest are again entering the
drug development pipeline.
The development of the United
Nations’ Convention on Biodiversity, a
pact between world governments
agreeing to commit to the environ-
ment and ecology in the face of
economic development, has had a
considerable impact on drug discovery
from natural products. The convention
identifies natural genetic resources as
part of the heritage of the countries in
which they are found and the tradi-
tional knowledge about plants to be
acknowledged as the intellectual prop-
erty of its holders. This means that
informed consent is required from the
stewards of the genetic resources—that
is, the traditional healers, for commer-
cial development. The benefits of the
research and development as well as
the financial rewards must be shared.
The Fogarty International Center of
the US National Institutes of Health
has developed a programme for
universities and businesses in devel-
oped countries to partner with institu-
tions or groups in developing coun-
tries to successfully implement the
convention. This effort is recognised as
the International Cooperative Biodi-
versity Group programme, with the
goals being the discovery of new
pharmaceuticals and agricultural
chemicals, scientific and economic
development, and conservation of
biodiversity.w12
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Foundation programme for
newly qualified doctors
Richard Hays thinks that the new UK foundation course
should improve specialist training but may lack capacity
Born of necessity, devel-oped with remarkableconsensus, and pilotedsuccessfully for a year, theUnited Kingdom’s new
foundation programme for medical
graduates has been launched.w1 The
programme aims to ensure that all
entrants to formal postgraduate spe-
cialist training have met the standards
required to progress to that particular
phase of lifelong learning.w2 Opinions
vary about the role of these reforms
and their impact on the medical educa-
tion system and workforce.
The programme focuses on per-
formance in the workplace, rather
than only knowledge and skills, largely
in response to recent scandals that
highlighted problems with clinical
governance, professional teamwork,
and practitioners’ honesty. The core
competencies required to complete the
programme match those laid down by
the General Medical Council in Good
Medical Practice and reflect reasonable
expectations of the ability of junior
medical practitioners.w3 Although the
UK may be the first to formalise such a
system, similar moves are being dis-
cussed in other places with similar
systems of medical education and
career progress.
The introduction of such pro-
grammes should not imply that medi-
cal schools are not doing their job.
Medical education is a long process. In
just four, five, or six years, medical
schools are expected to cover the basic
elements required for competent prac-
tice as a junior medical officer. The
foundation programme is meant to
ensure that these competences can be
applied under supervision in the work-
place. Learners learn more effectively
when they are responsible for their
actions, and it has always been the early
hospital years that allowed graduates to
develop the confidence to become
competent practitioners. The weakness
of the previous system has been the
lack of time, resources, and expertise
necessary to ensure that every junior
hospital doctor reaches that point.
The new system aims to make every
clinical experience a relevant, more
standardised, better supported, and
educationally valuable experience with
specific and achievable learning objec-
tives. Assessment will focus on practical
aspects of medical work rather than
examinations, and it will reward greater
engagement by learners. The pro-
gramme also brings new learning
opportunities—such as posts in public
health, primary care, and academia—
where junior doctors can sample a
broader range of options for hospital as
well as non-hospital careers.
And the complete package includes
bridges and shorter pathways to more
advanced specialist training, removing at
least some repetition of less valuable
learning experiences, and recognising
the more relevant and valuable place-
ments that contribute to the achievement
of specific career objectives. In summary,
the foundation programme has the
potential to provide a sound platform on
which to build future medical careers
more quickly and more flexibly.w4 As
usual, however, it is the implementation
of these reforms that raises the most
questions. Although the programme has
enormous potential for success, the
stakes are high, and failure may not be
forgiven. One response to the global
shortage of medical workforces has been
a rapid expansion of undergraduate
medical education into new secondary
and primary care facilities, where service
loads are high and educational resources
are stretched.w5 This means that the
foundation programme will be compet-
ing for learning opportunities with
medical schools and even with specialty
training programmes, and capacity may
not be sufficient for all levels of
education to expand quickly.
What will students and new doctors
make of these reforms? Junior doctors
might now be treated more like
students, rather than junior profession-
als who are adult learners. Current stu-
dents are reasonably concerned that
there may be insufficient posts, diluted
clinical experience, and the possibility
that some may not achieve the required
competences and be stranded without
a traditional career.w6 w7 And, although
there are advantages to identifying
graduates who are unsuited to clinical
careers at an early stage, will reasonable
alternatives be available?
The likely success of the programme
in moving medical graduates to a wider
range of specialties, including those
where the need is greatest, is hard to
judge. Workforce trends are difficult to
predict. The recent international down-
turn in demand for primary care and the
more general specialties may not recov-
er,w8 w9 trends towards subspecialisation
in primary and tertiary care may
continue, and new specialties will con-
tinue to emerge. Much of the pro-
gramme’s success in directing careers
may depend on whether, and to what
extent, learners have inspirational expe-
riences in such areas of need, and on the
tension created by pressure to ensure
that core competencies are also achieved
in more mainstream areas of medicine.
Furthermore, high quality teaching
and learning do not happen by
accident: a curriculum is initially no
more than a document. Medical
schools must engage with the founda-
tion programme, helping to develop
expertise in medical education and
ensuring that the years spent as junior
hospital doctors are part of a smooth
transition for graduates. There will have
to be rapid expansion in the number of
medical graduates who have been
taught to teach—those with formal
training in methods of teaching and
learning. Postgraduate training in
medical education may have to become
a formal requirement for at least some
clinicians in each teaching facility, and
medical education may develop into a
formal postgraduate medical specialty.
Lastly, the current difficult pathways for
medical practitioners to gain formal
educational qualifications may need to
be simplified, with more flexible profes-
sional doctorates or membership
courses. The success of the foundation
programme, then, will require genuine
academic development and support
throughout the entire healthcare
system, rather than in a relatively
small number of elite teaching facilities.
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